Human Papillomavirus Quadrivalent (Type 6,11,16 &18) Vaccine, Recombinant

Human papillomavirus quadrivalent vaccine, recombinant, is a non-infectious recombinant vaccine designed to protect against infection and disease caused by HPV types 6, 11, 16 and 18. It belongs to the papillomavirus vaccine class and contains purified virus-like particles (VLPs) made from the L1 major capsid proteins of these four HPV types. The VLPs contain no viral DNA and therefore cannot reproduce or cause HPV infection. After intramuscular administration, the vaccine stimulates the immune system to produce type-specific antibodies that can respond more rapidly if the vaccinated individual is subsequently exposed to the corresponding HPV types. HPV types 16 and 18 are associated with a substantial proportion of HPV-related cervical and other anogenital cancers, while types 6 and 11 account for most HPV-related genital warts. The quadrivalent vaccine is administered by intramuscular injection and is intended primarily for prevention before exposure to the relevant HPV types. It does not treat an existing HPV infection, established HPV-related cancer, or existing HPV-related lesions. The vaccine is clinically important because vaccination can reduce the risk of several HPV-associated precancerous lesions, cancers and genital warts caused by the HPV types included in the vaccine.

The quadrivalent HPV vaccine was developed using recombinant DNA technology to produce L1 proteins that self-assemble into non-infectious virus-like particles. The U.S. FDA originally approved GARDASIL in 2006, making it the first quadrivalent HPV vaccine licensed in the United States; subsequent regulatory reviews expanded and maintained its approved uses in specified age groups. The European Union authorised Gardasil in 2006, while the related EU product Silgard received marketing authorisation on 19 September 2006 before its authorisation was withdrawn in 2019 at the manufacturer's request for commercial reasons. In India, CDSCO records include Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant supplied by MSD, with a regulatory record dated 2 January 2023. FDA records continue to identify the quadrivalent vaccine as Gardasil, with the current regulatory record reflecting a 2 April 2025 approval update. Clinical development included large randomized studies evaluating prevention of HPV-related precancerous lesions, genital warts and other disease endpoints in females and males.

Human papillomavirus quadrivalent vaccine is used for active immunisation to prevent diseases caused by HPV types 6, 11, 16 and 18 in the age groups covered by the applicable product authorization. Approved uses have included prevention of cervical, vulvar, vaginal and anal cancers associated with HPV types 16 and 18, as well as cervical, vulvar, vaginal and anal precancerous or dysplastic lesions and genital warts caused by the vaccine HPV types. In males, approved uses include prevention of anal cancer, anal intraepithelial neoplasia and genital warts in the relevant age group. The vaccine is preventive rather than therapeutic and does not eliminate an existing HPV infection or treat established HPV-related disease. It may be administered as part of routine vaccination programs and may be given alongside other vaccines according to applicable immunisation recommendations. The exact age range and indications depend on the regulatory jurisdiction and product-specific authorization.

Human papillomavirus quadrivalent vaccine is administered by intramuscular injection, generally into the deltoid region or an appropriate alternative injection site. For individuals beginning vaccination before the 15th birthday, a two-dose schedule may be used in accordance with the applicable product recommendations, with the doses separated by several months. Individuals beginning vaccination at 15 years of age or older generally require a three-dose schedule, commonly given at approximately 0, 2 and 6 months. The minimum intervals between doses should follow the product-specific prescribing information and immunisation guidance; interrupted schedules generally do not require restarting the entire series. Vaccination should preferably be completed before exposure to HPV, although eligible individuals who have already been exposed to one HPV type may still receive protection against other vaccine HPV types to which they have not been exposed. Treatment duration is not applicable because this is a preventive vaccine series rather than ongoing drug therapy.

Common side effects are generally mild and temporary and include pain, redness or swelling at the injection site, headache, fever, nausea, dizziness and fatigue. Fainting can occur after vaccination, particularly among adolescents, and patients should therefore remain seated or observed for an appropriate period after injection. Local injection-site reactions may vary between individuals and usually resolve without specific treatment. The overall safety profile observed in clinical studies has generally been consistent with that expected for an injectable vaccine, although individual responses can vary.

Serious adverse events are uncommon, but severe allergic reactions including anaphylaxis can occur and require immediate medical treatment. The vaccine is contraindicated in individuals with a severe allergic reaction to a previous dose or to a vaccine component, including relevant yeast hypersensitivity according to product information. Syncope may occur following vaccination and can occasionally result in injury, so appropriate observation and precautions are recommended. Vaccination should generally be postponed in individuals with a moderate or severe acute illness until recovery, while a minor illness is not usually a reason to delay vaccination. If pregnancy is recognized after starting the series, remaining doses should generally be deferred until after pregnancy rather than administered during pregnancy; inadvertent vaccination during pregnancy is not generally considered an indication for intervention.

Before vaccination, healthcare professionals should review previous vaccine reactions, known allergies, current illness, pregnancy status and relevant immunisation history. The vaccine is not intended to replace routine cervical cancer screening because vaccination does not protect against every oncogenic HPV type and does not treat existing HPV infection. Immunocompromised individuals may have a reduced immune response, although vaccination may still be recommended according to applicable immunisation guidance. Concomitant immunosuppressive treatment can potentially reduce the immune response to vaccination. Quadrivalent HPV vaccine can generally be administered with other vaccines when recommended, using separate injection sites when appropriate. Classic drug interactions are uncommon because the vaccine does not undergo conventional drug metabolism, but the timing of vaccination may need consideration in people receiving therapies that substantially suppress immune function.

Verify the patient's age, previous HPV vaccine doses and the specific product before selecting the schedule, because dosing recommendations vary according to age at initiation and jurisdiction. Confirm that the vaccine is administered intramuscularly and that the correct dose and formulation are used. Patients should be counselled that the vaccine prevents new HPV infections and related disease but does not treat existing HPV infection, genital warts or established cervical abnormalities. Observe patients appropriately after vaccination because fainting can occur, particularly in adolescents. Maintain accurate documentation of product, dose, administration date and injection site. If a dose is delayed, continue the series according to the applicable schedule rather than automatically restarting it. Continue recommended cervical cancer screening after vaccination because protection is not complete against all HPV-associated cancer-causing types.